Botulinum toxin treatment of lateral axial dystonia in parkinsonism
Identifieur interne : 001151 ( Istex/Corpus ); précédent : 001150; suivant : 001152Botulinum toxin treatment of lateral axial dystonia in parkinsonism
Auteurs : Laura Bonanni ; Astrid Thomas ; Sara Varanese ; Vincenzo Scorrano ; Marco OnofrjSource :
- Movement Disorders [ 0885-3185 ] ; 2007-10-31.
English descriptors
Abstract
Lateral axial dystonia (LAD) has been described in patients with Parkinson's disease (PD), but treatment might be more controversial than treatment of LAD in other neurological conditions. Our study was designed as a blinded cross‐over with botulinum toxin (BTX) and placebo in order to investigate the efficacy of BTX in PD LAD. Nine patients with LAD who failed to experience benefit from oral medications were randomly assigned to 2 groups, 4 patients received BTX and 5 placebo as a first treatment, and were switched‐over to BTX or placebo in the following treatment session, performed 3 months after the first session. Each patient was evaluated at baseline, 2 and 4 weeks after injection and after 3 months follow‐up with the Trunk Dystonia Disability Scale (TDDS), a Visual Analogue Scale (VAS) and a goniometric measurement of the lateral displacement. Patients were videotaped at each visit. None of the patients of the placebo group experienced benefit from treatment. BTX treatment was effective in 6 patients. One patient reported subjective benefit, with improvement of VAS score and mild improvement of TDDS score, but with no improvement of flexion degree. Two patients did not report any benefit. Four patients opted to continue to receive BTX treatment for 2 years after the cross‐over study. Our study shows that BTX could be considered a possible treatment for LAD in parkinsonism. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21694
Links to Exploration step
ISTEX:3356E99C7EA40BB813365608ED79D30B616D8E2FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Botulinum toxin treatment of lateral axial dystonia in parkinsonism</title><author><name sortKey="Bonanni, Laura" sort="Bonanni, Laura" uniqKey="Bonanni L" first="Laura" last="Bonanni">Laura Bonanni</name><affiliation><mods:affiliation>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</mods:affiliation></affiliation></author><author><name sortKey="Thomas, Astrid" sort="Thomas, Astrid" uniqKey="Thomas A" first="Astrid" last="Thomas">Astrid Thomas</name><affiliation><mods:affiliation>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</mods:affiliation></affiliation></author><author><name sortKey="Varanese, Sara" sort="Varanese, Sara" uniqKey="Varanese S" first="Sara" last="Varanese">Sara Varanese</name><affiliation><mods:affiliation>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</mods:affiliation></affiliation></author><author><name sortKey="Scorrano, Vincenzo" sort="Scorrano, Vincenzo" uniqKey="Scorrano V" first="Vincenzo" last="Scorrano">Vincenzo Scorrano</name><affiliation><mods:affiliation>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</mods:affiliation></affiliation></author><author><name sortKey="Onofrj, Marco" sort="Onofrj, Marco" uniqKey="Onofrj M" first="Marco" last="Onofrj">Marco Onofrj</name><affiliation><mods:affiliation>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3356E99C7EA40BB813365608ED79D30B616D8E2F</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21694</idno><idno type="url">https://api.istex.fr/document/3356E99C7EA40BB813365608ED79D30B616D8E2F/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001151</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Botulinum toxin treatment of lateral axial dystonia in parkinsonism</title><author><name sortKey="Bonanni, Laura" sort="Bonanni, Laura" uniqKey="Bonanni L" first="Laura" last="Bonanni">Laura Bonanni</name><affiliation><mods:affiliation>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</mods:affiliation></affiliation></author><author><name sortKey="Thomas, Astrid" sort="Thomas, Astrid" uniqKey="Thomas A" first="Astrid" last="Thomas">Astrid Thomas</name><affiliation><mods:affiliation>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</mods:affiliation></affiliation></author><author><name sortKey="Varanese, Sara" sort="Varanese, Sara" uniqKey="Varanese S" first="Sara" last="Varanese">Sara Varanese</name><affiliation><mods:affiliation>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</mods:affiliation></affiliation></author><author><name sortKey="Scorrano, Vincenzo" sort="Scorrano, Vincenzo" uniqKey="Scorrano V" first="Vincenzo" last="Scorrano">Vincenzo Scorrano</name><affiliation><mods:affiliation>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</mods:affiliation></affiliation></author><author><name sortKey="Onofrj, Marco" sort="Onofrj, Marco" uniqKey="Onofrj M" first="Marco" last="Onofrj">Marco Onofrj</name><affiliation><mods:affiliation>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-10-31">2007-10-31</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">14</biblScope><biblScope unit="page" from="2097">2097</biblScope><biblScope unit="page" to="2103">2103</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">3356E99C7EA40BB813365608ED79D30B616D8E2F</idno><idno type="DOI">10.1002/mds.21694</idno><idno type="ArticleID">MDS21694</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease.</term><term>botulinum toxin</term><term>lateral axial dystonia</term><term>parkinsonism</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Lateral axial dystonia (LAD) has been described in patients with Parkinson's disease (PD), but treatment might be more controversial than treatment of LAD in other neurological conditions. Our study was designed as a blinded cross‐over with botulinum toxin (BTX) and placebo in order to investigate the efficacy of BTX in PD LAD. Nine patients with LAD who failed to experience benefit from oral medications were randomly assigned to 2 groups, 4 patients received BTX and 5 placebo as a first treatment, and were switched‐over to BTX or placebo in the following treatment session, performed 3 months after the first session. Each patient was evaluated at baseline, 2 and 4 weeks after injection and after 3 months follow‐up with the Trunk Dystonia Disability Scale (TDDS), a Visual Analogue Scale (VAS) and a goniometric measurement of the lateral displacement. Patients were videotaped at each visit. None of the patients of the placebo group experienced benefit from treatment. BTX treatment was effective in 6 patients. One patient reported subjective benefit, with improvement of VAS score and mild improvement of TDDS score, but with no improvement of flexion degree. Two patients did not report any benefit. Four patients opted to continue to receive BTX treatment for 2 years after the cross‐over study. Our study shows that BTX could be considered a possible treatment for LAD in parkinsonism. © 2007 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Laura Bonanni MD, PhD</name><affiliations><json:string>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</json:string><json:string>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</json:string></affiliations></json:item><json:item><name>Astrid Thomas MD, PhD</name><affiliations><json:string>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</json:string><json:string>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</json:string></affiliations></json:item><json:item><name>Sara Varanese MD</name><affiliations><json:string>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</json:string><json:string>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</json:string></affiliations></json:item><json:item><name>Vincenzo Scorrano MD</name><affiliations><json:string>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</json:string><json:string>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</json:string></affiliations></json:item><json:item><name>Marco Onofrj MD</name><affiliations><json:string>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</json:string><json:string>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>lateral axial dystonia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>parkinsonism</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>botulinum toxin</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease.</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Lateral axial dystonia (LAD) has been described in patients with Parkinson's disease (PD), but treatment might be more controversial than treatment of LAD in other neurological conditions. Our study was designed as a blinded cross‐over with botulinum toxin (BTX) and placebo in order to investigate the efficacy of BTX in PD LAD. Nine patients with LAD who failed to experience benefit from oral medications were randomly assigned to 2 groups, 4 patients received BTX and 5 placebo as a first treatment, and were switched‐over to BTX or placebo in the following treatment session, performed 3 months after the first session. Each patient was evaluated at baseline, 2 and 4 weeks after injection and after 3 months follow‐up with the Trunk Dystonia Disability Scale (TDDS), a Visual Analogue Scale (VAS) and a goniometric measurement of the lateral displacement. Patients were videotaped at each visit. None of the patients of the placebo group experienced benefit from treatment. BTX treatment was effective in 6 patients. One patient reported subjective benefit, with improvement of VAS score and mild improvement of TDDS score, but with no improvement of flexion degree. Two patients did not report any benefit. Four patients opted to continue to receive BTX treatment for 2 years after the cross‐over study. Our study shows that BTX could be considered a possible treatment for LAD in parkinsonism. © 2007 Movement Disorder Society</abstract><qualityIndicators><score>6.524</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1434</abstractCharCount><pdfWordCount>3788</pdfWordCount><pdfCharCount>23843</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>228</abstractWordCount></qualityIndicators><title>Botulinum toxin treatment of lateral axial dystonia in parkinsonism</title><genre><json:string>Serial article</json:string></genre><host><volume>22</volume><pages><total>7</total><last>2103</last><first>2097</first></pages><issn><json:string>0885-3185</json:string></issn><issue>14</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1002/mds.21694</json:string></doi><id>3356E99C7EA40BB813365608ED79D30B616D8E2F</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/3356E99C7EA40BB813365608ED79D30B616D8E2F/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/3356E99C7EA40BB813365608ED79D30B616D8E2F/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/3356E99C7EA40BB813365608ED79D30B616D8E2F/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Botulinum toxin treatment of lateral axial dystonia in parkinsonism</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2007</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Botulinum toxin treatment of lateral axial dystonia in parkinsonism</title><author><persName><forename type="first">Laura</forename><surname>Bonanni</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</affiliation><affiliation>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</affiliation></author><author><persName><forename type="first">Astrid</forename><surname>Thomas</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</affiliation><affiliation>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</affiliation></author><author><persName><forename type="first">Sara</forename><surname>Varanese</surname><roleName type="degree">MD</roleName></persName><affiliation>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</affiliation><affiliation>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</affiliation></author><author><persName><forename type="first">Vincenzo</forename><surname>Scorrano</surname><roleName type="degree">MD</roleName></persName><affiliation>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</affiliation><affiliation>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</affiliation></author><author><persName><forename type="first">Marco</forename><surname>Onofrj</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Neurophysiopathology, University G.D'Annunzio of Chieti‐Pescara, Via Fonte Romana, 65124 Pescara, Italy</p></note><affiliation>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</affiliation><affiliation>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-10-31"></date><biblScope unit="vol">22</biblScope><biblScope unit="issue">14</biblScope><biblScope unit="page" from="2097">2097</biblScope><biblScope unit="page" to="2103">2103</biblScope></imprint></monogr><idno type="istex">3356E99C7EA40BB813365608ED79D30B616D8E2F</idno><idno type="DOI">10.1002/mds.21694</idno><idno type="ArticleID">MDS21694</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Lateral axial dystonia (LAD) has been described in patients with Parkinson's disease (PD), but treatment might be more controversial than treatment of LAD in other neurological conditions. Our study was designed as a blinded cross‐over with botulinum toxin (BTX) and placebo in order to investigate the efficacy of BTX in PD LAD. Nine patients with LAD who failed to experience benefit from oral medications were randomly assigned to 2 groups, 4 patients received BTX and 5 placebo as a first treatment, and were switched‐over to BTX or placebo in the following treatment session, performed 3 months after the first session. Each patient was evaluated at baseline, 2 and 4 weeks after injection and after 3 months follow‐up with the Trunk Dystonia Disability Scale (TDDS), a Visual Analogue Scale (VAS) and a goniometric measurement of the lateral displacement. Patients were videotaped at each visit. None of the patients of the placebo group experienced benefit from treatment. BTX treatment was effective in 6 patients. One patient reported subjective benefit, with improvement of VAS score and mild improvement of TDDS score, but with no improvement of flexion degree. Two patients did not report any benefit. Four patients opted to continue to receive BTX treatment for 2 years after the cross‐over study. Our study shows that BTX could be considered a possible treatment for LAD in parkinsonism. © 2007 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>lateral axial dystonia</term></item><item><term>parkinsonism</term></item><item><term>botulinum toxin</term></item><item><term>Parkinson's disease.</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2007-04-02">Received</change><change when="2007-07-08">Registration</change><change when="2007-10-31">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/3356E99C7EA40BB813365608ED79D30B616D8E2F/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="140"><doi origin="wiley" registered="yes">10.1002/mds.v22:14</doi><numberingGroup><numbering type="journalVolume" number="22">22</numbering><numbering type="journalIssue">14</numbering></numberingGroup><coverDate startDate="2007-10-31">31 October 2007</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="140" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21694</doi><idGroup><id type="unit" value="MDS21694"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2007 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2007-04-02"></event><event type="manuscriptRevised" date="2007-07-04"></event><event type="manuscriptAccepted" date="2007-07-08"></event><event type="publishedOnlineEarlyUnpaginated" date="2007-08-08"></event><event type="firstOnline" date="2007-08-08"></event><event type="publishedOnlineFinalForm" date="2007-10-26"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.6 mode:FullText source:FullText result:FullText" date="2010-04-21"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2097</numbering><numbering type="pageLast">2103</numbering></numberingGroup><correspondenceTo>Neurophysiopathology, University G.D'Annunzio of Chieti‐Pescara, Via Fonte Romana, 65124 Pescara, Italy</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21694.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="24"></count><count type="wordTotal" number="4367"></count></countGroup><titleGroup><title type="main" xml:lang="en">Botulinum toxin treatment of lateral axial dystonia in parkinsonism</title><title type="short" xml:lang="en">Treatment of LAD in Parkinsonism</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Laura</givenNames><familyName>Bonanni</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Astrid</givenNames><familyName>Thomas</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Sara</givenNames><familyName>Varanese</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Vincenzo</givenNames><familyName>Scorrano</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>Marco</givenNames><familyName>Onofrj</familyName><degrees>MD</degrees></personName><contactDetails><email>onofrj@unich.it</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="IT" type="organization"><unparsedAffiliation>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="IT" type="organization"><unparsedAffiliation>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">lateral axial dystonia</keyword><keyword xml:id="kwd2">parkinsonism</keyword><keyword xml:id="kwd3">botulinum toxin</keyword><keyword xml:id="kwd4">Parkinson's disease.</keyword></keywordGroup><supportingInformation><p> This article includes supplementary video clips, available online at <url href="http://www.interscience.wiley.com/jpages/0885-3185/suppmat"> http://www.interscience.wiley.com/jpages/0885–3185/suppmat </url> . </p></supportingInformation><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Lateral axial dystonia (LAD) has been described in patients with Parkinson's disease (PD), but treatment might be more controversial than treatment of LAD in other neurological conditions. Our study was designed as a blinded cross‐over with botulinum toxin (BTX) and placebo in order to investigate the efficacy of BTX in PD LAD. Nine patients with LAD who failed to experience benefit from oral medications were randomly assigned to 2 groups, 4 patients received BTX and 5 placebo as a first treatment, and were switched‐over to BTX or placebo in the following treatment session, performed 3 months after the first session. Each patient was evaluated at baseline, 2 and 4 weeks after injection and after 3 months follow‐up with the Trunk Dystonia Disability Scale (TDDS), a Visual Analogue Scale (VAS) and a goniometric measurement of the lateral displacement. Patients were videotaped at each visit. None of the patients of the placebo group experienced benefit from treatment. BTX treatment was effective in 6 patients. One patient reported subjective benefit, with improvement of VAS score and mild improvement of TDDS score, but with no improvement of flexion degree. Two patients did not report any benefit. Four patients opted to continue to receive BTX treatment for 2 years after the cross‐over study. Our study shows that BTX could be considered a possible treatment for LAD in parkinsonism. © 2007 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Botulinum toxin treatment of lateral axial dystonia in parkinsonism</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Treatment of LAD in Parkinsonism</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Botulinum toxin treatment of lateral axial dystonia in parkinsonism</title></titleInfo><name type="personal"><namePart type="given">Laura</namePart><namePart type="family">Bonanni</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</affiliation><affiliation>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Astrid</namePart><namePart type="family">Thomas</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</affiliation><affiliation>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sara</namePart><namePart type="family">Varanese</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</affiliation><affiliation>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Vincenzo</namePart><namePart type="family">Scorrano</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</affiliation><affiliation>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Marco</namePart><namePart type="family">Onofrj</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Neurophysiopathology, University G. D'Annunzio of Chieti‐Pescara, Italy</affiliation><affiliation>G. D'Annunzio Foundation, Aging Research Center, CE.S.I., University G.D'Annunzio of Chieti, Pescara, Italy</affiliation><description>Correspondence: Neurophysiopathology, University G.D'Annunzio of Chieti‐Pescara, Via Fonte Romana, 65124 Pescara, Italy</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2007-10-31</dateIssued><dateCaptured encoding="w3cdtf">2007-04-02</dateCaptured><dateValid encoding="w3cdtf">2007-07-08</dateValid><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">1</extent><extent unit="references">24</extent><extent unit="words">4367</extent></physicalDescription><abstract lang="en">Lateral axial dystonia (LAD) has been described in patients with Parkinson's disease (PD), but treatment might be more controversial than treatment of LAD in other neurological conditions. Our study was designed as a blinded cross‐over with botulinum toxin (BTX) and placebo in order to investigate the efficacy of BTX in PD LAD. Nine patients with LAD who failed to experience benefit from oral medications were randomly assigned to 2 groups, 4 patients received BTX and 5 placebo as a first treatment, and were switched‐over to BTX or placebo in the following treatment session, performed 3 months after the first session. Each patient was evaluated at baseline, 2 and 4 weeks after injection and after 3 months follow‐up with the Trunk Dystonia Disability Scale (TDDS), a Visual Analogue Scale (VAS) and a goniometric measurement of the lateral displacement. Patients were videotaped at each visit. None of the patients of the placebo group experienced benefit from treatment. BTX treatment was effective in 6 patients. One patient reported subjective benefit, with improvement of VAS score and mild improvement of TDDS score, but with no improvement of flexion degree. Two patients did not report any benefit. Four patients opted to continue to receive BTX treatment for 2 years after the cross‐over study. Our study shows that BTX could be considered a possible treatment for LAD in parkinsonism. © 2007 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>lateral axial dystonia</topic><topic>parkinsonism</topic><topic>botulinum toxin</topic><topic>Parkinson's disease.</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><note type="content"> This article includes supplementary video clips, available online at http://www.interscience.wiley.com/jpages/0885–3185/suppmat .</note><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><detail type="issue"><caption>no.</caption><number>14</number></detail><extent unit="pages"><start>2097</start><end>2103</end><total>7</total></extent></part></relatedItem><identifier type="istex">3356E99C7EA40BB813365608ED79D30B616D8E2F</identifier><identifier type="DOI">10.1002/mds.21694</identifier><identifier type="ArticleID">MDS21694</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2007 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001151 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001151 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:3356E99C7EA40BB813365608ED79D30B616D8E2F
|texte= Botulinum toxin treatment of lateral axial dystonia in parkinsonism
}}
| This area was generated with Dilib version V0.6.23. |  |